Nautilus Biotechnology (NAUT) Cash from Investing Activities Growth (1y) (2021 - 2026)
Nautilus Biotechnology (NAUT) Cash from Investing Activities Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 62.68% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -674.01% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -166.24% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Nautilus Biotechnology | 212.11 Mn | 116.24 Mn | - | -27.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.05% |
| Dec 31, 2025 | -97.88% |
| Sep 30, 2025 | 106.02% |
| Jun 30, 2025 | 1.26% |
| Mar 31, 2025 | -12.71% |
| Dec 31, 2024 | 190.37% |
| Sep 30, 2024 | -157.38% |
| Jun 30, 2024 | 733.88% |
| Mar 31, 2024 | 265.64% |
| Dec 31, 2023 | 35.90% |
| Sep 30, 2023 | 209.48% |
| Jun 30, 2023 | -106.43% |
| Mar 31, 2023 | -188.89% |
| Dec 31, 2022 | -1,156.32% |
| Sep 30, 2022 | 85.78% |
| Jun 30, 2022 | 141.48% |
| Mar 31, 2022 | -35.45% |
| Dec 31, 2021 | 104.06% |
| Sep 30, 2021 | 43.83% |